AN

Allen R. Nissenson

Board Member at Oxidien Pharmaceuticals

Dr. Nissenson is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, where he previously served as Director of the Dialysis Program and Associate Dean. Dr. Nissenson also holds the position of Emeritus Chief Medical Officer of DaVita Kidney Care, having served as Chief Medical Officer for over 11 years. He recently joined Sentien Biotech as Chief Medical Officer. He is the immediate past Chair of Kidney Care Partners and immediate past Co-Chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. Dr. Nissenson served as a Robert Wood Johnson Health Policy Fellow of the Institute of Medicine, working as a health advisor to the late Senator Paul Wellstone. Dr. Nissenson currently serves on the Board of Directors of Angion Biomedica and Rockwell Medical.

Dr. Nissenson earned his M.D. from Northwestern University Medical School. Dr. Nissenson is the author of two dialysis textbooks, both in their fifth editions and was the founding Editor-in-Chief of Advances in Renal Replacement Therapy, an official journal of the National Kidney Foundation. He recently completed service as Editor-in-Chief of Hemodialysis International the official journal of the International Society for Hemodialysis, as well as Medscape Nephrology, an innovate website focused on nephrology. He has over 740 publications in the field of nephrology, dialysis, anemia management, and health care delivery and policy, the latter including a seminal paper in Health Affairs on the end-stage renal disease (ESRD) program. Among his numerous honors is the President’s Award of the National Kidney Foundation. In addition, in 2007 he received the Lifetime Achievement Award in Hemodialysis presented by the University of Missouri on behalf of the Annual Dialysis Conference.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Oxidien Pharmaceuticals

Clinical-stage drug development company addressing an unmet need in kidney disease using a proven oral biologic enzyme


Employees

1-10

Links